Business Context and Reporting Period
This Form 8-K Current Report was filed by Spero Therapeutics, Inc. on February 5, 2024, regarding events occurring on that date and a separation agreement dated February 9, 2024. The filing addresses the departure of a senior executive officer.
Key Financial Metrics
The filing does not provide general financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the specific severance and compensation package for the departing officer:
- Severance Payment: $356,298.75 (nine months of base salary).
- Pro-rated Cash Bonus: $34,266.98 (payable in 2025).
- Consulting Rate: $395.00 per hour for a nine-month term.
Material Changes
The primary material change is the departure of Tamara Joseph, Chief Legal Officer and Corporate Secretary, effective March 6, 2024. She is leaving to pursue other interests. The company has entered into a Separation Agreement and a Consulting Agreement to facilitate her transition.
Outlook, Risks, and Unusual Items
Management Commentary: CEO Sath Shukla thanked Ms. Joseph for her contributions and leadership.
Compensatory Arrangements: Ms. Joseph will receive continued salary payments, a pro-rated bonus, and will provide consulting services on an hourly basis. Her equity awards (options and RSUs) will continue to vest during the consulting term, with a 90-day exercise window post-termination.
Risks/Contingencies: The filing notes that the descriptions of the agreements are subject to the actual terms of the Separation and Consulting Agreements, which will be filed as exhibits to the Form 10-K for the year ended December 31, 2023.
Investor Verification Checklist
- Verify the exact terms of the Separation and Consulting Agreements in the upcoming Form 10-K exhibits.
- Confirm the timeline for the appointment of a new Chief Legal Officer and Corporate Secretary.
- Monitor the impact of the executive departure on ongoing legal matters or regulatory compliance.
- Review the company's cash position to ensure it can support the immediate severance and future consulting costs.